• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重的α1-抗胰蛋白酶缺乏症(PiZZ)个体与具有已知吸烟习惯的一般人群的生存比较。

Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.

机构信息

Dept of Respiratory Medicine, Skåne University Hospital, Lund University, Lund, Sweden

Dept of Clinical Sciences, Division of Respiratory Medicine and Allergology, Lund University, Lund, Sweden.

出版信息

Eur Respir J. 2017 Sep 9;50(3). doi: 10.1183/13993003.00198-2017. Print 2017 Sep.

DOI:10.1183/13993003.00198-2017
PMID:28889108
Abstract

Knowledge about the natural history of severe alpha 1-antitrypsin (AAT) deficiency (PiZZ) is limited. Our aim was to compare the survival of PiZZ individuals with randomly selected controls from the Swedish general population.The PiZZ subjects (n=1585) were selected from the Swedish National AATD Register. The controls (n=5999) were randomly selected from the Swedish population register. Smoking habits were known for all subjects.Median follow-up times for the PiZZ subjects (731 never-smokers) and controls (3179 never-smokers) were 12 and 17 years, respectively (p<0.001). During follow-up, 473 PiZZ subjects (30%), and 747 controls (12%) died. The PiZZ subjects had a significantly shorter survival time than the controls, p<0.001. After adjustment for gender, age, smoking habits and presence of respiratory symptoms, the risk of death was still significantly higher for the PiZZ individuals than for the controls, hazard ratio (HR) 3.2 (95% CI 2.8-3.6; p<0.001). By contrast, the risk of death was not increased in never-smoking PiZZ individuals identified by screening, compared to never-smoking controls, HR 1.2 (95% CI 0.6-2.2).The never-smoking PiZZ individuals identified by screening had a similar life expectancy to the never-smokers in the Swedish general population. Early diagnosis of AAT deficiency is of utmost importance.

摘要

关于严重的α1-抗胰蛋白酶(AAT)缺乏症(PiZZ)自然史的知识有限。我们的目的是比较 PiZZ 个体与瑞典普通人群中随机选择的对照者的生存率。

PiZZ 受试者(n=1585)从瑞典国家 AATD 登记处中选出。对照组(n=5999)从瑞典人口登记处中随机选择。所有受试者的吸烟习惯均已知。PiZZ 受试者(731 名从不吸烟者)和对照组(3179 名从不吸烟者)的中位随访时间分别为 12 年和 17 年(p<0.001)。随访期间,473 名 PiZZ 受试者(30%)和 747 名对照者(12%)死亡。PiZZ 受试者的生存时间明显短于对照组,p<0.001。调整性别、年龄、吸烟习惯和呼吸道症状后,PiZZ 个体的死亡风险仍然明显高于对照组,风险比(HR)为 3.2(95% CI 2.8-3.6;p<0.001)。相比之下,通过筛查发现的从不吸烟的 PiZZ 个体与从不吸烟的对照者相比,死亡风险并未增加,HR 为 1.2(95% CI 0.6-2.2)。通过筛查发现的从不吸烟的 PiZZ 个体的预期寿命与瑞典普通人群中的从不吸烟者相似。早期诊断 AAT 缺乏症至关重要。

相似文献

1
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.严重的α1-抗胰蛋白酶缺乏症(PiZZ)个体与具有已知吸烟习惯的一般人群的生存比较。
Eur Respir J. 2017 Sep 9;50(3). doi: 10.1183/13993003.00198-2017. Print 2017 Sep.
2
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.通过新生儿筛查确定的瑞典α1-抗胰蛋白酶缺乏队列在37至40岁时的健康状况和肺功能。
Int J Chron Obstruct Pulmon Dis. 2017 Feb 2;12:495-500. doi: 10.2147/COPD.S120241. eCollection 2017.
3
Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).严重α-1抗胰蛋白酶缺乏症(PiZZ型)非吸烟者的临床病程及预后
Thorax. 2008 Dec;63(12):1091-5. doi: 10.1136/thx.2008.095497. Epub 2008 Aug 5.
4
The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.瑞典 α1-抗胰蛋白酶筛选研究:34 岁时的健康状况以及肺和肝功能。
Ann Am Thorac Soc. 2015 Jun;12(6):807-12. doi: 10.1513/AnnalsATS.201410-452OC.
5
Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.严重的α1-抗胰蛋白酶缺乏症(PiZZ)个体患缺血性心脏病的风险低于普通人群。
Int J Chron Obstruct Pulmon Dis. 2020 Jun 4;15:1245-1252. doi: 10.2147/COPD.S247377. eCollection 2020.
6
Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.37至39岁α-1抗胰蛋白酶缺乏个体的肺功能与CT肺密度测定
Int J Chron Obstruct Pulmon Dis. 2018 Nov 8;13:3689-3698. doi: 10.2147/COPD.S167497. eCollection 2018.
7
Survival in severe alpha-1-antitrypsin deficiency (PiZZ).严重的α-1-抗胰蛋白酶缺乏症(PiZZ)患者的存活率。
Respir Res. 2010 Apr 26;11(1):44. doi: 10.1186/1465-9921-11-44.
8
Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.与瑞典普通人群相比,严重α1抗胰蛋白酶缺乏症患者的特定病因死亡率。
Int J Chron Obstruct Pulmon Dis. 2016 Jul 26;11:1663-9. doi: 10.2147/COPD.S109173. eCollection 2016.
9
Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.重度吸烟会缩小α-1-抗胰蛋白酶缺乏症基因型 PiZZ 和 PiSZ 之间生活质量和恶化频率的差异。
Respir Med. 2017 Sep;130:1-8. doi: 10.1016/j.rmed.2017.07.004. Epub 2017 Jul 8.
10
Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.30 岁α-1-抗胰蛋白酶缺乏症个体的肺功能。
Respir Med. 2009 Jun;103(6):861-5. doi: 10.1016/j.rmed.2008.12.021. Epub 2009 Feb 1.

引用本文的文献

1
Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: data from the EARCO international registry.α1抗胰蛋白酶缺乏症(AATD)相关慢性阻塞性肺疾病(COPD)患者的临床特征随诊断年龄而异:来自EARCO国际注册研究的数据
BMC Pulm Med. 2025 Jul 4;25(1):321. doi: 10.1186/s12890-025-03782-y.
2
Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.PiSZ和PiZZ型α-1抗胰蛋白酶缺乏症的进展与强化治疗:一项纵向功能和密度测定研究
Biomolecules. 2025 Apr 17;15(4):599. doi: 10.3390/biom15040599.
3
Epidemiology and outcomes of alpha-1 antitrypsin deficiency in Sweden 2002-2020: A population-based cohort study of 2286 individuals.
2002 - 2020年瑞典α-1抗胰蛋白酶缺乏症的流行病学与转归:一项基于人群的队列研究,涉及2286名个体。
J Intern Med. 2025 Mar;297(3):300-311. doi: 10.1111/joim.20058. Epub 2025 Jan 8.
4
Bronchiectasis Occurs Independently of Chronic Obstructive Pulmonary Disease in Alpha-1 Antitrypsin Deficiency.在α-1抗胰蛋白酶缺乏症中,支气管扩张独立于慢性阻塞性肺疾病发生。
Chronic Obstr Pulm Dis. 2024 Sep 27;11(5):507-514. doi: 10.15326/jcopdf.2024.0526.
5
Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series.与严重α-1 抗胰蛋白酶缺乏症相关的肺气肿的增强治疗的个体化指征:病例系列。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241271917. doi: 10.1177/17534666241271917.
6
Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study.重组α-1抗胰蛋白酶-Fc融合蛋白INBRX-101用于α-1抗胰蛋白酶缺乏症成人患者:一项1期研究。
Chronic Obstr Pulm Dis. 2024 May 29;11(3):282-292. doi: 10.15326/jcopdf.2023.0469.
7
Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint.九个关于α-1 抗胰蛋白酶缺乏症增强治疗的有争议问题:观点。
Eur Respir Rev. 2023 Dec 6;32(170). doi: 10.1183/16000617.0170-2023. Print 2023 Dec 31.
8
The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry.诊断延迟对 α-1 抗胰蛋白酶缺乏症患者生存的影响:来自奥地利 α-1 肺脏注册研究的数据。
Respir Res. 2023 Jan 27;24(1):34. doi: 10.1186/s12931-023-02338-0.
9
Registry-based cohort study of alpha-1 antitrypsin deficiency prevalence, incidence and mortality in Denmark 2000-2018.基于登记的丹麦 2000-2018 年α-1 抗胰蛋白酶缺乏症患病率、发病率和死亡率的队列研究。
BMJ Open Respir Res. 2022 Dec;9(1). doi: 10.1136/bmjresp-2022-001281.
10
Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients.住院COVID-19患者中轻度α-1抗胰蛋白酶缺乏症的低患病率
Int J Gen Med. 2022 Jun 28;15:5843-5848. doi: 10.2147/IJGM.S370434. eCollection 2022.